LON:DPH

Dechra Pharmaceuticals Share Forecast, Price & News

GBX 3,850

+54.00 (+1.42 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

3,764

Now: GBX 3,850▼

3,888

50-Day Range

3,272

MA: GBX 3,444.48▼

3,796

52-Week Range

2,443.80

Now: GBX 3,850▼

3,888

Volume306,597 shs

Average Volume211,677 shs

Market Capitalization£4.16 billion

P/E Ratio93.00

Dividend Yield0.92%

BetaN/A

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Industry, Sector and Symbol

Stock Exchange LON

Industry Drug Manufacturers - Major

Sub-IndustryN/A

SectorMedical

Current SymbolLON:DPH

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.dechra.com

Phone+44-1606-814730

Employees1,889

Year FoundedN/A

Debt

Debt-to-Equity Ratio54.85

Current Ratio2.79

Quick Ratio1.73

Price-To-Earnings

Trailing P/E Ratio93.00

Forward P/E Ratio0.39

P/E GrowthN/A

Sales & Book Value

Annual Sales£566.40 million

Price / Sales7.35

Cash FlowGBX 128.60 per share

Price / Cash Flow29.94

Book ValueGBX 578.70 per share

Price / Book6.65

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares108,169,000

Market Cap£4.16 billion

Next Earnings DateN/A

OptionableNot Optionable

Headlines

Dechra Pharmaceuticals (LON:DPH) Reaches New 52-Week High at $3,888.00
April 17, 2021 | americanbankingnews.com

Dechra Pharmaceuticals (LON:DPH) Stock Passes Above 200-Day Moving Average of $3,452.17
April 14, 2021 | americanbankingnews.com

Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine
April 12, 2021 | finance.yahoo.com

Dechra Pharmaceuticals (LON:DPH) Shareholders Have Enjoyed An Impressive 201% Share Price Gain
April 9, 2021 | finance.yahoo.com

Dechra Pharmaceuticals (LON:DPH) Shares Cross Above Two Hundred Day Moving Average of $3,438.66
April 6, 2021 | americanbankingnews.com

Canine Arthritis Treatment Market is expected to grow at a CAGR of ~ 4% during the forecast period of 2019-2029
March 1, 2021 | marketwatch.com

NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis Treatment Market
March 1, 2021 | marketwatch.com

Animal Antibiotics and Antimicrobials Market Latest Research On Industry Growth, Trends, Top Players, & Key Regions By 2027
February 22, 2021 | marketwatch.com

Companion Animal Products Boost Lifts Dechra's Half-Year Profit
February 22, 2021 | lse.co.uk

Canine Arthritis Treatment Market Latest Research On Industry Growth, Trends, Top Players, & Key Regions By 2027
February 16, 2021 | marketwatch.com

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for AKS-425c, a Once-a-Week Insulin Therapy for Cats
February 9, 2021 | businesswire.com

Dechra Pharmaceuticals In Tri-Solfen Deal, Ups Medical Ethics Stake
February 8, 2021 | lse.co.uk

Dechra Pharmaceuticals PLC's (LON:DPH) Intrinsic Value Is Potentially 18% Below Its Share Price
February 8, 2021 | finance.yahoo.com

Global Animal Antimicrobials Market 2020 Industry Key Player, Trend and Segmented Data, Demand and Forecast by 2025
February 3, 2021 | marketwatch.com

Veterinary Therapeutics market growth at a CAGR of ~ 6.2% from 2020 to 2027
February 3, 2021 | marketwatch.com

Global Animal Antimicrobials Market 2020 Segmentation, Future Business Strategy, Manufacturers Analysis and Forecast by 2025
February 2, 2021 | marketwatch.com

Animal Antibiotics and Antimicrobials Market Analysis, Trends, Growth, Size, Share and Forecast 2019 to 2025
January 30, 2021 | marketwatch.com

Canine Arthritis Treatment Market Analysis, Trends, Growth, Size, Share and Forecast 2020 to 2026
January 29, 2021 | marketwatch.com

Dechra Pharmaceuticals Ahead Of Expectations Despite Uncertainty
January 14, 2021 | lse.co.uk

Veterinary Therapeutics Market to Reach Valuation US$ 58.6 Billion by 2027
January 8, 2021 | marketwatch.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.04 out of 5 stars

1.3 Analyst's Opinion

Consensus Rating
Dechra Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 3,350, Dechra Pharmaceuticals has a forecasted downside of 13.0% from its current price of GBX 3,850.
Amount of Analyst Coverage
Dechra Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Dechra Pharmaceuticals has received 336 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Dechra Pharmaceuticals has received 387 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Dechra Pharmaceuticals has received 53.53% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Dechra Pharmaceuticals and other stocks. Vote “Outperform” if you believe DPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Dechra Pharmaceuticals has a dividend yield of 0.92%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Dechra Pharmaceuticals does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Dechra Pharmaceuticals is 84.54%. Payout ratios above 75% are not desirable because they may not be sustainable.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dechra Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought £19,838.70 in company stock and sold GBX 0 in company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Dechra Pharmaceuticals is 93.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.03.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dechra Pharmaceuticals is 93.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 45.42.
Price to Book Value per Share Ratio
Dechra Pharmaceuticals has a P/B Ratio of 6.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

GBX 3,850

+54.00 (+1.42 %)

(As of 04/16/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive DPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DPH and its competitors with MarketBeat's FREE daily newsletter.

Dechra Pharmaceuticals (LON:DPH) Frequently Asked Questions

Is Dechra Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Dechra Pharmaceuticals stock.
View analyst ratings for Dechra Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Dechra Pharmaceuticals?

Wall Street analysts have given Dechra Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Dechra Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Dechra Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Dechra Pharmaceuticals' stock was trading at GBX 2,472 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DPH stock has increased by 55.7% and is now trading at GBX 3,850.
View which stocks have been most impacted by COVID-19.

How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?

Dechra Pharmaceuticals declared a dividend on Monday, February 22nd. Investors of record on Thursday, March 4th will be paid a dividend of GBX 11.11 per share on Wednesday, April 7th. This represents a dividend yield of 0.32%. The ex-dividend date of this dividend is Thursday, March 4th. The official announcement can be accessed at this link.
View Dechra Pharmaceuticals' dividend history.

Is Dechra Pharmaceuticals a good dividend stock?

Dechra Pharmaceuticals pays an annual dividend of GBX 35 per share and currently has a dividend yield of 0.92%. The dividend payout ratio of Dechra Pharmaceuticals is 84.54%. Payout ratios above 75% are not desirable because they may not be sustainable.
View Dechra Pharmaceuticals' dividend history.

What price target have analysts set for DPH?

4 brokers have issued 1-year price targets for Dechra Pharmaceuticals' stock. Their forecasts range from GBX 3,085 to GBX 3,600. On average, they anticipate Dechra Pharmaceuticals' stock price to reach GBX 3,350 in the next twelve months. This suggests that the stock has a possible downside of 13.0%.
View analysts' price targets for Dechra Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Dechra Pharmaceuticals' key executives?

Dechra Pharmaceuticals' management team includes the following people:

Mr. Ian D. Page, CEO, MD & Exec. Director (Age 60, Pay $793k)
Mr. Paul Nicholas Sandland MAAT, FCCA, CFO & Exec. Director (Age 42, Pay $375.6k)
Dr. Anthony Gerard Griffin, MD of Dechra Veterinary Products for Europe & Exec. Director (Age 58, Pay $466k)
Dr. Susan Longhofer, Chief Scientific Officer (Age 63)
Ms. Katy Clough, Group HR Director
Mr. Mike Eldred, Pres of North America (Age 51)
Ms. Melanie Hall, Company Sec.

Who are some of Dechra Pharmaceuticals' key competitors?

Some companies that are related to Dechra Pharmaceuticals include Hutchison China MediTech (HCM), Vectura Group (VEC), Beximco Pharmaceuticals (BXP), ECO Animal Health Group (EAH), Allergy Therapeutics (AGY), Futura Medical (FUM), Trilogy International Partners (TRL), Sareum Holdings plc (SAR.L) (SAR), Avivagen (VIV), N4 Pharma (N4P), Cathay International Holdings Limited (CTI.L) (CTI), Antisense Therapeutics (ANP), Bayer Aktiengesellschaft (BAYN), Mayne Pharma Group (MAYNF) and Mayne Pharma Group (MYX).
View all of DPH's competitors.

What other stocks do shareholders of Dechra Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include (TTR.L) (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SEB (SKP) and Barratt Developments (BDEV).

What is Dechra Pharmaceuticals' stock symbol?

Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How do I buy shares of Dechra Pharmaceuticals?

Shares of DPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Dechra Pharmaceuticals' stock price today?

One share of DPH stock can currently be purchased for approximately GBX 3,850.

How much money does Dechra Pharmaceuticals make?

Dechra Pharmaceuticals has a market capitalization of £4.16 billion and generates £566.40 million in revenue each year.

How many employees does Dechra Pharmaceuticals have?

Dechra Pharmaceuticals employs 1,889 workers across the globe.

What is Dechra Pharmaceuticals' official website?

The official website for Dechra Pharmaceuticals is www.dechra.com.

Where are Dechra Pharmaceuticals' headquarters?

Dechra Pharmaceuticals is headquartered at 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom.

How can I contact Dechra Pharmaceuticals?

Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company can be reached via phone at +44-1606-814730.

This page was last updated on 4/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here